RLN2 and metabolic dysfunction-associated steatohepatitis: Targeting eNOS may also be a strategy for attenuating NASH development; mice treated with relaxin-2 increased hepatic eNOS activation and attenuated Kupffer cell and stellate cell activation in methionine–choline-deficient (MCD) diet-induced NASH (Lee et al., 2019).